PranaX Corporation

PranaX Corporation, based in the US, specializes in developing and manufacturing exosome-based products that enhance health and quality of life through innovative therapeutic solutions. Founded in 2022 and headquartered in Houston, US, PranaX Corporation focuses on exosome technology to deliver health benefits. The company has successfully completed its first deal and raised USD 17. 00 mn in Series A funding on January 29, 2026, to further its operations and product development.

PranaX specializes in the research, development, and manufacturing of exosome-based products designed to deliver transformative health benefits aimed at enhancing and restoring quality of life. Their core offerings revolve around innovative therapies utilizing exosomes, which are small extracellular vesicles involved in intercellular communication and capable of carrying bioactive molecules that support immune regulation, tissue regeneration, and neurological functions. These products target a broad range of end-user applications, particularly in regenerative medicine and wellness, seeking to address aging-related ailments and promote overall health improvement. PranaX serves a diverse clientele, including healthcare providers, researchers, and wellness centers across North America, Europe, and Asia, emphasizing their commitment to pushing the boundaries of biomedical research and application in various geographical markets.

While specific revenue figures for PranaX are not disclosed, the company operates within a structured transaction model that encompasses B2B partnerships and direct-to-consumer sales channels for its exosome-based products. Transactions typically involve collaborations with healthcare institutions and clinics that integrate PranaX’s therapies into their treatment offerings, as well as potential direct sales to consumers seeking wellness solutions. The pricing model for these products reflects the innovative nature of the therapies and their developmental complexity. PranaX’s flagship offerings, which underscore their commitment to evidence-based exosome innovation, are positioned to cater to both the clinical and consumer health markets, facilitating a multifaceted approach to revenue generation through strategic partnerships and direct product engagement.

PranaX Corporation plans to leverage the USD 17. 00 mn raised in Series A funding to bolster its research initiatives, enhance operational and scientific systems, support collaborations, and advance its products toward development and commercialization. The company is also focused on expanding into new geographic markets and regions, although specific details on the targeted areas and upcoming product releases have not been disclosed.